Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ModraDoc006/r Phase I in mCRPC
NCT03136640Phase 1Completed
- Sponsor
- Modra Pharmaceuticals
- Start
- Apr 2017
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ModraDoc006 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Modra Pharmaceuticals. Primary endpoint: Maximum Tolerated Dose at 4 weeks. Started Apr 2017; status: completed.
02
Drugs
ModraDoc006
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03136640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03136640.